PSEN1 and Alzheimer disease: Metabolic alterations, including deficits in acylcarnitines, have previously been reported in brains of a transgenic mouse model of AD bearing mutated APP and PS1 transgenes, in which early brain amyloid deposition and cognitive impairment occur (36).